Storia in 2 fonti

India pharma sector shifts focus to biosimilars, biologics and high-value growth

India pharma sector moves beyond generics to biosimilars, biologics and AI-driven manufacturing, strengthening exports and global competitiveness.

Raccontata da

economictimes.indiatimes.com

thehindubusinessline.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

thehindubusinessline.comStai leggendo17 h fa

India pharma sector shifts focus to biosimilars, biologics and high-value growth

India pharma sector moves beyond generics to biosimilars, biologics and AI-driven manufacturing, strengthening exports and global competitiveness.

originale

economictimes.indiatimes.com2 g fa

Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal Manchanda

Indian pharma targets $500M-$1B biosimilar revenue in 4-5 years, shifting from US generic dependence as FDA approvals delay. Companies diversify into higher-margin innovation and CDMO, countering commodity margin compression; Biocon, Dr Reddy's, Lupin lead pipeline maturation.

Leggi questa versione → originale

Timeline cronologica

martedì 23 giugno 2026·economictimes.indiatimes.com
Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal Manchanda
India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and consumer healthcare. While US FDA…
mercoledì 24 giugno 2026·thehindubusinessline.com
India pharma sector shifts focus to biosimilars, biologics and high-value growth
India pharma sector moves beyond generics to biosimilars, biologics and AI-driven manufacturing, strengthening exports and global competitiveness.